Curapath and Cristal Therapeutics sign co-exclusive license of CliCr® bioconjugation platform

Paterna, Valencia, SPAIN and Maastricht, THE NETHERLANDS – 26 November 2025, Curapath, a leading innovator in the development and manufacturing of polymer and lipid-based drug delivery systems, and Cristal Therapeutics, a biotech company developing innovative conjugation technologies, today announced they entered into a co-exclusive license agreement for the CliCr® bioconjugation platform. The platform offers a powerful and scalable solution for efficient, site-specific and stable conjugation of biomolecules, addressing a critical challenge in active targeting and targeted drug delivery to extrahepatic tissues.
Under the agreement, Curapath will be the exclusive contract manufacturer (CDMO) to apply CliCr® bioconjugation for the delivery of nucleic acids via targeted polymeric and lipid nanoparticles (LNPs). Cristal Therapeutics and Curapath will both have the right to grant sublicenses in this exciting and rapidly expanding field.

Dr. Philippe Clavel, CEO of Curapath, stated: “Active targeting remains one of the greatest challenges in advanced drug delivery. By integrating Cristal Therapeutics’ CliCr® platform, Curapath strengthens its leadership in next-generation delivery systems, including targeting LNPs to extrahepatic tissues. This alliance enables us to offer innovators a scalable, precise, and stable bioconjugation solution, accelerating the development of safer, more effective targeted therapies.”

Dr. Werner Cautreels, CEO of Cristal Therapeutics, commented: “We are very pleased to collaborate with Curapath, a strong and leading CDMO in the LNP field. This collaboration places CliCr® in an excellent position to become the standard in bioconjugation to nanoparticles for nucleic acid drug delivery. It is another example for the broad applicability of the CliCr® platform in therapeutic drug and diagnostic development.”

More information can be found here: 251126 Press release Curapath – Cristal